Edgar Filing: MONSANTO CO /NEW/ - Form 8-K

MONSANTO CO /NEW/ Form 8-K April 10, 2015

### **UNITED STATES**

# SECURITIES AND EXCHANGE COMMISSION

# **WASHINGTON, DC 20549**

### FORM 8-K

# **CURRENT REPORT**

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): April 7, 2015

### MONSANTO COMPANY

(Exact Name of Registrant as Specified in its Charter)

Delaware (State or Other Jurisdiction **001-16167** (Commission

43-1878297 (IRS Employer

of Incorporation)

File Number) 800 North Lindbergh Boulevard **Identification No.)** 

# Edgar Filing: MONSANTO CO /NEW/ - Form 8-K

# St. Louis, Missouri 63167

(Address of Principal Executive Offices) (Zip Code)

Registrant s telephone number, including area code: (314) 694-1000

### **Not Applicable**

(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- "Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### **Item 8.01 Other Events.**

On April 7, 2015, Monsanto Company (the <u>Company</u>) entered into an underwriting agreement (the <u>Underwriting Agreement</u>, which term includes the Pricing Agreement attached thereto as Exhibit I) with Goldman, Sachs & Co. and Merrill Lynch, Pierce, Fenner & Smith Incorporated as representatives of the underwriters named therein (collectively, the <u>Underwriters</u>), related to the sale by the Company of (i) \$300,000,000 principal amount of its 2.850% Senior Notes due 2025 (the <u>Notes due 2025</u>), and (ii) \$500,000,000 principal amount of its 3.950% Senior Notes due 2045 (the <u>Notes due 2045</u> and, together with the Notes due 2025, the <u>Notes</u>). The Notes were issued on April 10, 2015 pursuant to an Indenture (the <u>Indenture</u>), dated as of July 1, 2014, by and between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (the <u>Trustee</u>).

In connection with the offering of the Notes, we are filing this Current Report on Form 8-K to add the following exhibits to the Company s Registration Statement on Form S-3 (File No. 333-197036): (i) the Underwriting Agreement and Pricing Agreement (Exhibit 1.1 to this Current Report on Form 8-K), (ii) the forms of Notes (Exhibits 4.1 and 4.2 to this Current Report on Form 8-K) and (iii) the opinion of counsel with respect to the status of the Notes as binding obligations (Exhibit 5.1 to this Current Report on Form 8-K).

#### Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

- 1.1 Underwriting Agreement and Pricing Agreement, dated as of April 7, 2015, by and among Monsanto Company and Goldman, Sachs & Co. and Merrill Lynch, Pierce, Fenner & Smith Incorporated, as representatives of the Underwriters.
- 4.1 Form of 2.850% Note due 2025.
- 4.2 Form of 3.950% Note due 2045.
- 5.1 Opinion of Bryan Cave LLP.
- 23.1 Consent of Bryan Cave LLP (included in Exhibit 5.1).

2

# **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

# MONSANTO COMPANY

Date: April 10, 2015 By: /s/ Jennifer L. Woods

Name: Jennifer L. Woods Title: Assistant Secretary

3

### **EXHIBIT INDEX**

- 1.1 Underwriting Agreement and Pricing Agreement, dated as of April 7, 2015, by and among Monsanto Company and Goldman, Sachs & Co. and Merrill Lynch, Pierce, Fenner & Smith Incorporated, as representatives of the Underwriters.
- 4.1 Form of 2.850% Note due 2025.
- 4.2 Form of 3.950% Note due 2045.
- 5.1 Opinion of Bryan Cave LLP.
- 23.1 Consent of Bryan Cave LLP (included in Exhibit 5.1).

4